Currently, inhibition of PD-1/PD-L1 interaction to restore anti-tumor immunity has shown a remarkably durable clinical response rate in patients, notably in melanoma, renal, lung, prostate and bladder carcinoma (Llosa et al., 2015). Here, CD274 is linked to neoplasm.